Diagnosis, Natural History and Treatment of Eosinophilic Enteritis: a Review

  • Guillaume Pineton de ChambrunEmail author
  • Gaspard Dufour
  • Barbara Tassy
  • Benjamin Rivière
  • Najima Bouta
  • Michael Bismuth
  • Fabrizio Panaro
  • Natalie Funakoshi
  • Jeanne Ramos
  • Jean-Christophe Valats
  • Pierre Blanc
Small Intestine (D Sachar, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Small Intestine


Purpose of Review

To review recent findings regarding eosinophilic enteritis, including epidemiology, pathogenesis, natural history, and treatment.

Recent Findings

A 2017 population-based study using a US healthcare system database identified 1820 patients with a diagnosis of eosinophilic enteritis among 35,826,830 individuals. The majority of patients with eosinophilic enteritis in this study were women (57.7%), Caucasian (77.5%), and adults (> 18 years of age) (83.5%). The overall prevalence of eosinophilic enteritis was estimated at 5.1/100,000 persons.


Eosinophilic enteritis, also known as eosinophilic gastroenteritis, is a rare primary eosinophilic gastrointestinal disorder (EGID) of unknown etiology characterized by the presence of an intense eosinophilic infiltrate on histopathological examination of the intestinal mucosa. The etiology of eosinophilic enteritis remains unknown. However, there is evidence to support the role of allergens in the pathogenesis of this disorder, as children and adults with EGIDs often have positive skin testing to food allergens and a family history of allergic diseases. Recent studies unraveling the role of IgE-mediated but also delayed Th2-type responses have provided insight into the pathogenesis of this disease. Eosinophilic enteritis causes a wide array of gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, vomiting, bloating, or ascites, and its diagnosis requires a high degree of clinical likelihood, given the nonspecific clinical presentation and physical examination findings. Oral corticosteroids are considered to be the mainstay of treatment and are generally used for a short period with good response rates. Antihistamine drugs and sodium cromoglycate have also been used to treat patients with eosinophilic enteritis. Preliminary studies have demonstrated the potential benefit of biological therapies targeting the eosinophilic pathway such as mepolizumab, an anti-IL5 antibody, or omalizumab, an anti-IgE monoclonal antibody. Eosinophilic enteritis is generally considered to be a benign disease without relapse, but up to 50% of patients may present a more complex natural history characterized by unpredictable relapses and a chronic course.


Eosinophils Gastroenteritis Natural history Allergy Treatment Corticosteroids 


Compliance with Ethical Standards

Conflict of Interest

Guillaume Pineton de Chambrun reports personal fees from MSD, Abbvie, Takeda, Ferring Pharmaceuticals, and Hospira as a lecturer and consultant, outside the submitted work.

Gaspard Dufour, Barbara Tassy, Benjamin Rivière, Najima Bouta, Michael Bismuth, Fabrizio Panaro, Natalie Funakoshi, Jeanne Ramos, Jean-Christophe Valats, and Pierre Blanc declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: •• Of major Importance

  1. 1.
    •• Mansoor E, Saleh MA, Cooper GS. Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017. Clin Gastroenterol Hepatol. 2017;15(11):1733–41. This recent population-based study, using an United States healthcare system database, identified 1,820 patients with a diagnosis of EE among 35,826,830 individuals in the database from 2012 to 2017. The majority of patients with EE in this study were women (57.7%), Caucasian (77.5%), and adults (>18 years of age) (83.5%). The overall prevalence of eosinophilic enteritis was estimated to 5.1/100,000 persons.CrossRefPubMedGoogle Scholar
  2. 2.
    Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore). 1970;49(4):299–319.CrossRefGoogle Scholar
  3. 3.
    Yan BM, Shaffer EA. Primary eosinophilic disorders of the gastrointestinal tract. Gut. 2009;58(5):721–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Pineton de Chambrun G, Desreumaux P, Cortot A. Eosinophilic enteritis. Dig Dis. 2015;33(2):183–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Kaijser R. Zur Kenntnis der allergischen Affektionen des Verdauungs-Kanals vom Standpunkt des Chirurgien aus. Arch Klin Chir. 1937;188:36–64.Google Scholar
  6. 6.
    Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut. 1990;31(1):54–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pineton de Chambrun G, Gonzalez F, Canva JY, Gonzalez S, Houssin L, Desreumaux P, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2011;9(11):950–6 e1, 956.e1.Google Scholar
  8. 8.
    •• Abou Rached A, El Hajj W. Eosinophilic gastroenteritis: approach to diagnosis and management. World J Gastrointest Pharmacol Ther. 2016;7(4):513–23. In this recent review of the literature, authors exhaustively summarized data about oesinophilic enteritis managment and treatments with comprehensive proposed algorithms.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ingle SB, Hinge Ingle CR. Eosinophilic gastroenteritis: an unusual type of gastroenteritis. World J Gastroenterol. 2013;19(31):5061–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004;113(1):11–28. quiz 9 CrossRefPubMedGoogle Scholar
  11. 11.
    Lowichik A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. Mod Pathol 1996;9(2):110–114.Google Scholar
  12. 12.
    Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE. Eosinophilic gastroenteritis: clinical experience with 15 patients. World J Gastroenterol. 2003;9(12):2813–6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Desreumaux P, Colombel JF. Diagnostic étiologique d'une éosinophilie digestive. Rev Prat. 1992;171:668–73.Google Scholar
  14. 14.
    de Weck AL. Drug allergy, immunotherapy, immune complexes and anaphylaxis. Curr Opin Immunol. 1989;2(4):548–57.CrossRefPubMedGoogle Scholar
  15. 15.
    Khan S. Eosinophilic gastroenteritis. Best Pract Res Clin Gastroenterol. 2005;19(2):177–98.CrossRefPubMedGoogle Scholar
  16. 16.
    Klion A. Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med. 2009;60:293–306.CrossRefPubMedGoogle Scholar
  17. 17.
    Kinoshita Y, Furuta K, Ishimaura N, Ishihara S, Sato S, Maruyama R, et al. Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis. J Gastroenterol. 2013;48(3):333–9.Google Scholar
  18. 18.
    Lee CM, Changchien CS, Chen PC, Lin DY, Sheen IS, Wang CS, et al. Eosinophilic gastroenteritis: 10 years experience. Am J Gastroenterol. 1993;88(1):70–4.Google Scholar
  19. 19.
    Naylor AR. Eosinophilic gastroenteritis. Scott Med J. 1990;35(6):163–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang L, Duan L, Ding S, Lu J, Jin Z, Cui R, et al. Eosinophilic gastroenteritis: clinical manifestations and morphological characteristics, a retrospective study of 42 patients. Scand J Gastroenterol. 2011;46(9):1074–80.Google Scholar
  21. 21.
    •• Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a National Administrative Database. J Pediatr Gastroenterol Nutr. 2016;62(1):36–42. This recent study used databases representative of a U.S. national commercially-insured population containing medical and pharmaceutical claims for >75million individuals to identify cases of eosinophilic gastritis, gastroenteritis, and colitis. In this study, the standardized estimated prevalences of eosinophilic gastritis, gastroenteritis, and colitis were 6.3/100,000, 8.4/100,000, and 3.3/100,000, respectively. The prevalence of eosinophilic gastroenteritis was highest among children age < 5 years. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Spergel JM, Book WM, Mays E, Song L, Shah SS, Talley NJ, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr. 2011;52(3):300–6.Google Scholar
  23. 23.
    Chang JY, Choung RS, Lee RM, Locke GR 3rd, Schleck CD, Zinsmeister AR, et al. A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2010;8(8):669–75. quiz e88Google Scholar
  24. 24.
    Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest. 1999;103(12):1719–27.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38(5):709–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol. 2009;101:81–121.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Desreumaux P, Seguy D, Dutoit E, Dubucquoi S, Colombel JF. La gastroentérites à éosinophiles. Hépato-Gastro. 1996;3(4):279–86.Google Scholar
  28. 28.
    Torpier G, Colombel JF, Mathieu-Chandelier C, Capron M, Dessaint JP, Cortot A, et al. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol. 1988;74(3):404–8.Google Scholar
  29. 29.
    Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147–74.CrossRefPubMedGoogle Scholar
  30. 30.
    •• Shoda T, Matsuda A, Arai K, Shimizu H, Morita H, Orihara K, et al. Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. J Allergy Clin Immunol. 2016;138(1):299–303. This recent study analyzed the sera of 13 infants with EE and demonstrated an increase level of thymic stromal lymphopoietin and IL-33 which are recognized as key cytokines in allergic disorders. Google Scholar
  31. 31.
    •• Song DJ, Shim MH, Lee N, Yoo Y, Choung JT. CCR3 monoclonal antibody inhibits eosinophilic inflammation and mucosal injury in a mouse model of eosinophilic gastroenteritis. Allergy Asthma Immunol Res. 2017;9(4):360–7. This recent study investigated the role of CCR-3 which acts as the receptor of eotaxine-1 in the development of eosinophilic gastrointestinal disease. This experimental study demonstrated that anti-CCR3 antibody significantly reduced the severity of eosinophilic inflammation, mucosal injury, and diarrhea in a mouse model of food allergen induced GI eosinophilic inflammation. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    •• Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. Dig Liver Dis. 2015;47(3):197–201. This recent retrospective cohor study identified patients with oesinophilic enteritis based on Pathology reports of all patients who had undergone upper endoscopy with biopsy between 2000 and 2013. In this study, 44 patients were diagnosed with oesinophilic enteritis and were evaluated with a mean follow-up of 26.2 months. CrossRefPubMedGoogle Scholar
  33. 33.
    Coton T. Gastroentérite à éosinophiles. Encyclopédie Médico-chirurgicale. 2009;[9–089-C-40].Google Scholar
  34. 34.
    Katz AJ, Goldman H, Grand RJ. Gastric mucosal biopsy in eosinophilic (allergic) gastroenteritis. Gastroenterology. 1977;73(4 Pt 1):705–9.PubMedGoogle Scholar
  35. 35.
    Navab F, Kleinman MS, Algazy K, Schenk E, Turner MD. Endoscopic diagnosis of eosinophilic gastritis. Gastrointest Endosc. 1972;19(2):67–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Endo H, Hosono K, Inamori M, Kato S, Uchiyama T, Iida H, et al. Capsule endoscopic evaluation of eosinophilic enteritis before and after treatment. Digestion. 2011;83(1–2):134–5.Google Scholar
  37. 37.
    Attar A, Cazals-Hatem D, Ponsot P. Videocapsule endoscopy identifies stenoses missed by other imaging techniques in a patient with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol: the official clinical practice journal of the American Gastroenterological Association. 2011;9(1):A28.Google Scholar
  38. 38.
    Busoni VB, Lifschitz C, Christiansen S, GdD MT, Orsi M. Eosinophilic gastroenteropathy: a pediatric series. Arch Argent Pediatr. 2011;109(1):68–73.PubMedGoogle Scholar
  39. 39.
    Elsing C, Placke J, Gross-Weege W. Budesonide for the treatment of obstructive eosinophilic jejunitis. Z Gastroenterol. 2007;45(2):187–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Lombardi C, Salmi A, Passalacqua G. An adult case of eosinophilic pyloric stenosis maintained on remission with oral budesonide. Eur Ann Allergy Clin Immunol. 2011;43(1):29–30.PubMedGoogle Scholar
  41. 41.
    Lombardi C, Salmi A, Savio A, Passalacqua G. Localized eosinophilic ileitis with mastocytosis successfully treated with oral budesonide. Allergy. 2007;62(11):1343–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Russel MG, Zeijen RN, Brummer RJ, de Bruine AP, van Kroonenburgh MJ, Stockbrugger RW. Eosinophilic enterocolitis diagnosed by means of technetium-99m albumin scintigraphy and treated with budesonide (CIR). Gut. 1994;35(10):1490–2.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Shahzad G, Moise D, Lipka S, Rizvon K, Mustacchia PJ. Eosinophilic enterocolitis diagnosed by means of upper endoscopy and colonoscopy with random biopsies treated with budenoside: a case report and review of the literature. ISRN Gastroenterol. 2011;2011:608901.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Siewert E, Lammert F, Koppitz P, Schmidt T, Matern S. Eosinophilic gastroenteritis with severe protein-losing enteropathy: successful treatment with budesonide. Dig Liver Dis. 2006;38(1):55–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Tan AC, Kruimel JW, Naber TH. Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets. Eur J Gastroenterol Hepatol. 2001;13(4):425–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Netzer P, Gschossmann JM, Straumann A, Sendensky A, Weimann R, Schoepfer AM. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol. 2007;19(10):865–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30.Google Scholar
  48. 48.
    Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007;120(3):594–601.Google Scholar
  49. 49.
    Turner D, Wolters VM, Russell RK, Shakhnovich V, Muise AM, Ledder O, et al. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. 2013;56(5):492–7.Google Scholar
  50. 50.
    Melamed I, Feanny SJ, Sherman PM, Roifman CM. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am J Med. 1991;90(3):310–4.CrossRefPubMedGoogle Scholar
  51. 51.
    De Maeyer N, Kochuyt AM, Van Moerkercke W, Hiele M. Montelukast as a treatment modality for eosinophilic gastroenteritis. Acta Gastroenterol Belg. 2011;74(4):570–5.PubMedGoogle Scholar
  52. 52.
    Friesen CA, Kearns GL, Andre L, Neustrom M, Roberts CC, Abdel-Rahman SM. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004;38(3):343–51.CrossRefPubMedGoogle Scholar
  53. 53.
    Neustrom MR, Friesen C. Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol. 1999;104(2 Pt 1):506.CrossRefPubMedGoogle Scholar
  54. 54.
    Quack I, Sellin L, Buchner NJ, Theegarten D, Rump LC, Henning BF. Eosinophilic gastroenteritis in a young girl—long term remission under Montelukast. BMC Gastroenterol. 2005;5:24.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Schwartz DA, Pardi DS, Murray JA. Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci. 2001;46(8):1787–90.CrossRefPubMedGoogle Scholar
  56. 56.
    Vanderhoof JA, Young RJ, Hanner TL, Kettlehut B. Montelukast: use in pediatric patients with eosinophilic gastrointestinal disease. J Pediatr Gastroenterol Nutr. 2003;36(2):293–4.CrossRefPubMedGoogle Scholar
  57. 57.
    Perez-Millan A, Martin-Lorente JL, Lopez-Morante A, Yuguero L, Saez-Royuela F. Subserosal eosinophilic gastroenteritis treated efficaciously with sodium cromoglycate. Dig Dis Sci. 1997;42(2):342–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Guillaume Pineton de Chambrun
    • 1
    • 2
    Email author
  • Gaspard Dufour
    • 1
    • 2
  • Barbara Tassy
    • 1
    • 2
  • Benjamin Rivière
    • 2
    • 3
  • Najima Bouta
    • 1
    • 2
  • Michael Bismuth
    • 1
    • 2
  • Fabrizio Panaro
    • 2
    • 4
  • Natalie Funakoshi
    • 5
  • Jeanne Ramos
    • 2
    • 3
  • Jean-Christophe Valats
    • 1
    • 2
  • Pierre Blanc
    • 1
    • 2
  1. 1.Gastroenterology Department, Saint-Eloi HospitalMontpellier University HospitalMontpellierFrance
  2. 2.School of MedicineMontpellier UniversityMontpellierFrance
  3. 3.Pathology Department, Gui de Chauliac HospitalMontpellier University HospitalMontpellierFrance
  4. 4.Digestive Surgery and Transplantation Department, Saint-Eloi HospitalMontpellier University HospitalMontpellierFrance
  5. 5.Department of Gastroenterology, Mersey Community HospitalTasmanian Health Service North West RegionLatrobeAustralia

Personalised recommendations